Alpha Cognition vs Lineage Cell Therapeutics
Lineage Cell Therapeutics is the larger business, with $14.6m of revenue in fiscal 2025 against $10.2m for Alpha Cognition (1.4 times as much). Alpha Cognition kept more of each dollar of sales as profit: a net margin of -202.2% against -436.5%.
| Latest fiscal year | Alpha CognitionACOG, 2025 | Lineage Cell TherapeuticsLCTX, 2025 |
|---|---|---|
| Revenue | $10.2m | $14.6m |
| Revenue growth | — | 53.2% |
| Net income | −$20.7m | −$63.5m |
| Operating margin | -221.7% | — |
| Net margin | -202.2% | -436.5% |
| Return on equity | -33.1% | -103.4% |
| Free cash flow | −$20.7m | −$19.4m |
| Cash | $66.0m | $40.8m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 71 | 77 |
| Market value | $179m | $252m |
| Price vs our value range | — | — |
| Moat score | — | 21 (Weak) |
| Insider trades, 12 months | 60 buys, 0 sales | 1 buys, 0 sales |